Dr. Phil Shaffer and I are back in SC to testify yet again against a bill that would permit unsupervised NP and PA practice after 2,000 hours of experience. In this episode, I share subcommittee chair Senator Tom Davis's perspectives that SC will lose funding from the Rural Health Transformation project without scope expansion. You'll also hear a letter of support from the FTC Office of Policy Planning supporting scope expansion, and PPP's response explaining why the FTC should reconsider it'...
All content for Patients at Risk is the property of Rebekah Bernard MD and Niran Al-Agba MD and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Dr. Phil Shaffer and I are back in SC to testify yet again against a bill that would permit unsupervised NP and PA practice after 2,000 hours of experience. In this episode, I share subcommittee chair Senator Tom Davis's perspectives that SC will lose funding from the Rural Health Transformation project without scope expansion. You'll also hear a letter of support from the FTC Office of Policy Planning supporting scope expansion, and PPP's response explaining why the FTC should reconsider it'...
There are an estimated 500-750 clinics across the U.S. providing infusions of Ketamine for the treatment of a variety of medical conditions. This is big business, estimated to bring in $3.1 billion per year and projected to rise to 6.9 billion by 2030. But is Ketamine safe and effective? Psychiatrist Kristina Kise, MD discusses the use of ketamine infusions in psychiatry, including the potential dangers to patients when physicians are not directly involved in drug oversight. ...
Patients at Risk
Dr. Phil Shaffer and I are back in SC to testify yet again against a bill that would permit unsupervised NP and PA practice after 2,000 hours of experience. In this episode, I share subcommittee chair Senator Tom Davis's perspectives that SC will lose funding from the Rural Health Transformation project without scope expansion. You'll also hear a letter of support from the FTC Office of Policy Planning supporting scope expansion, and PPP's response explaining why the FTC should reconsider it'...
